Identifying immune responses in a specific fibrotic disease

Who could benefit from this research

What this research studies

This research investigates the immune mechanisms involved in IgG4-related disease (IgG4-RD), a condition characterized by fibrosis and immune response abnormalities. The project focuses on identifying specific self-proteins that trigger these immune responses, which could lead to better understanding and treatment options for patients. Dr. Perugino, the principal investigator, is enhancing his skills in molecular biology and statistical analysis to conduct this research effectively. The study employs advanced techniques such as single-cell sequencing and peptide-MHC yeast display libraries to explore the immune landscape of IgG4-RD.

Why it matters

Where this research is happening

• Massachusetts General Hospital
  Boston, United States Active

Researchers

• Principal investigator: Perugino, Cory — Massachusetts General Hospital
• Study coordinator: Perugino, Cory

Related research

Other NIH-funded projects on the same topics.

• Mass General IgG4-related Disease Center

  This center follows people with IgG4-related disease to learn how immune cells, antibodies, and the microbiome drive flare-ups and remissions.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11323975

• Dermal priming to boost flu vaccine response in people on B cell depletion

  This study tests whether applying a topical cream with imiquimod on the skin around vaccination can boost the body’s response to the flu shot in people who are receiving B cell–depleting therapy.

  Recruiting Cambridge University Hospitals NHS Foundation Trust · Cambridge · NCT07925996

• FAPI‑74 PET/CT versus FDG PET/CT for inflammation in FUO, IgG4‑RD, and axial spondyloarthritis

  This project will test whether [18F]-AlF-FAPI-74 PET/CT finds inflammation more accurately than standard [18F]-FDG PET/CT in people with fever of unknown origin, IgG4‑related disease, or axial spondyloarthritis.

  Recruiting Phase 2/3 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07535554

• Anti-BCMA-CD19 CAR-T therapy for relapsed or refractory IgG4-related disease

  This trial will test a personalized CAR-T cell therapy that targets BCMA and CD19 in adults (18–75) whose IgG4-related disease has come back or not responded to standard treatments like steroids or rituximab.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07148791

• Comparing low- and higher-dose lenalidomide plus prednisone versus prednisone alone for active proliferative IgG4‑related disease

  This 52-week randomized trial will test whether adding 5 mg or 10 mg lenalidomide to prednisone helps adults with active proliferative IgG4‑related disease do better than prednisone alone.

  Recruiting Phase 2/3 Peking Union Medical College Hospital · Beijing · NCT07068165

• ACE1831 cell therapy for safety, effectiveness, and persistence in people with IgG4-related disease

  This trial will test ACE1831, an off-the-shelf gamma delta T cell therapy from healthy donors, to see if it is safe and helps adults with active IgG4-related disease.

  Recruiting at 11 sites Phase 1/2 Acepodia Biotech, Inc. · Atlanta, Georgia and 10 other locations · NCT07061938

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.